(VIANEWS) – Sterling Construction Company (STRL), STAAR Surgical Company (STAA), Uber (UBER) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Sterling Construction Company (STRL)
19.3% sales growth and 23.61% return on equity
Sterling Construction Company, Inc., a construction company, engages in the heavy civil, specialty services, and residential construction activities primarily in the southern United States, the Rocky Mountain states, California, and Hawaii. The company undertakes various heavy civil construction projects, including highways, roads, bridges, airfields, ports, light rail, water, wastewater and storm drainage systems for the departments of transportation in various states, regional transit authorities, airport authorities, port authorities, water authorities, and railroads. It offers specialty services such as foundations for multi-family homes, parking structures, and other commercial concrete projects for blue-chip end users in the e-commerce, data center, distribution center and warehousing, energy, mixed use, and multi-family sectors. The company also undertakes concrete foundations for single-family homes. In addition, it provides surveying, clearing and grubbing, erosion control, grading, grassing, site excavation, storm drainage, sanitary sewer and water main installation, drilling and blasting, curb and gutter, paving, concrete work, and landfill services. The company was formerly known as Oakhurst Company, Inc. and changed its name to Sterling Construction Company, Inc. in November 2001. Sterling Construction Company, Inc. was founded in 1955 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, Sterling Construction Company has a trailing twelve months EPS of $3.81.
PE Ratio
Sterling Construction Company has a trailing twelve months price to earnings ratio of 20.58. Meaning, the purchaser of the share is investing $20.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.61%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 1.9% and positive 29.7% for the next.
Sales Growth
Sterling Construction Company’s sales growth is 17% for the ongoing quarter and 19.3% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.7%, now sitting on 1.93B for the twelve trailing months.
Volume
Today’s last reported volume for Sterling Construction Company is 175425 which is 55.5% below its average volume of 394234.
2. STAAR Surgical Company (STAA)
18.1% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 83.42. Meaning, the purchaser of the share is investing $83.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Volume
Today’s last reported volume for STAAR Surgical Company is 579013 which is 35.3% below its average volume of 894954.
Moving Average
STAAR Surgical Company’s value is below its 50-day moving average of $32.98 and way below its 200-day moving average of $47.29.
Earnings Before Interest, Taxes, Depreciation, and Amortization
STAAR Surgical Company’s EBITDA is 235.92.
Yearly Top and Bottom Value
STAAR Surgical Company’s stock is valued at $31.70 at 00:22 EST, way under its 52-week high of $81.81 and way above its 52-week low of $27.00.
3. Uber (UBER)
13.6% sales growth and 11.79% return on equity
Uber Technologies, Inc. develops and operates proprietary technology applications in the United States, Canada, Latin America, Europe, the Middle East, Africa, and Asia excluding China and Southeast Asia. It operates through three segments: Mobility, Delivery, and Freight. The Mobility segment connects consumers with a range of transportation modalities, such as ridesharing, carsharing, micromobility, rentals, public transit, taxis, and other modalities; and offers riders in a variety of vehicle types, as well as financial partnerships products and advertising services. The Delivery segment allows to search for and discover restaurants to grocery, alcohol, convenience, and other retails; order a meal or other items; and Uber direct, a white-label Delivery-as-a-Service for retailers and restaurants, as well as advertising. The Freight segment manages transportation and logistics network, which connects shippers and carriers in digital marketplace including carriers upfronts, pricing, and shipment booking; and provides on-demand platform to automate logistics end-to-end transactions for small-and medium-sized business to global enterprises. Uber Technologies, Inc. was formerly known as Ubercab, Inc. and changed its name to Uber Technologies, Inc. in February 2011. The company was founded in 2009 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Uber has a trailing twelve months EPS of $0.52.
PE Ratio
Uber has a trailing twelve months price to earnings ratio of 126.12. Meaning, the purchaser of the share is investing $126.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.79%.
Volume
Today’s last reported volume for Uber is 10493700 which is 67.52% below its average volume of 32316500.
Sales Growth
Uber’s sales growth is 13.5% for the present quarter and 13.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 41.4% and positive 350% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Uber’s EBITDA is 181.86.
Previous days news about Uber(UBER)
- According to CNBC on Sunday, 28 January, "Big companies such as Dollar Tree, Kroger, Hilton, McDonald’s, Target, Uber and Walmart now also offer employees early access to paychecks."
4. SSR Mining (SSRM)
11.9% sales growth and 5.57% return on equity
SSR Mining Inc., together with its subsidiaries, engages in the acquisition, exploration, development, and operation of precious metal resource properties in Turkey and the Americas. The company explores for gold, silver, copper, lead, and zinc deposits. Its projects include the Çöpler Gold mine located in Erzincan, Turkey; the Marigold mine located in Humboldt County, Nevada, the United States; the Seabee Gold Operation located in Saskatchewan, Canada; and the Puna Operations in Jujuy, Argentina. The company was formerly known as Silver Standard Resources Inc. and changed its name to SSR Mining Inc. in August 2017. SSR Mining Inc. was incorporated in 1946 and is based in Denver, Colorado.
Earnings Per Share
As for profitability, SSR Mining has a trailing twelve months EPS of $1.
PE Ratio
SSR Mining has a trailing twelve months price to earnings ratio of 9.8. Meaning, the purchaser of the share is investing $9.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Volume
Today’s last reported volume for SSR Mining is 1720990 which is 24.82% below its average volume of 2289410.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SSR Mining’s EBITDA is 22.02.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 9, 2023, the estimated forward annual dividend rate is 0.28 and the estimated forward annual dividend yield is 2.86%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 183.3% and 20%, respectively.
5. Hyster (HY)
10.9% sales growth and 48.4% return on equity
Hyster-Yale Materials Handling, Inc., through its subsidiaries, designs, engineers, manufactures, sells, and services a line of lift trucks, attachments, and aftermarket parts worldwide. It manufactures components, such as frames, masts, and transmissions; and assembles lift trucks. The company markets its products primarily under the Hyster and Yale brand names to independent Hyster and Yale retail dealerships. It also sells aftermarket parts under the Hyster and Yale, as well as UNISOURCE and PREMIER brands to Hyster and Yale dealers for the service of competitor lift trucks. In addition, the company produces and distributes attachments, forks, and lift tables under the Bolzoni, Auramo, and Meyer brand names; and designs and produces products in the port equipment and rough terrain forklift markets. Further, it designs, manufactures, and sells hydrogen fuel-cell stacks and engines. The company serves light and heavy manufacturers, trucking and automotive companies, rental companies, building materials and paper suppliers, lumber, metal products, warehouses, retailers, food distributors, container handling companies, and U.S. and non-U.S. governmental agencies. Hyster-Yale Materials Handling, Inc. was incorporated in 1991 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, Hyster has a trailing twelve months EPS of $6.28.
PE Ratio
Hyster has a trailing twelve months price to earnings ratio of 10.58. Meaning, the purchaser of the share is investing $10.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.4%.
Sales Growth
Hyster’s sales growth is 7.9% for the present quarter and 10.9% for the next.
Moving Average
Hyster’s worth is way above its 50-day moving average of $55.66 and way above its 200-day moving average of $49.54.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Hyster’s EBITDA is 16.9.
Volume
Today’s last reported volume for Hyster is 81371 which is 5.49% below its average volume of 86101.
6. Transcat (TRNS)
9.8% sales growth and 7.52% return on equity
Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management software that is used to integrate and manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, oil and gas and alternative energy, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.
Earnings Per Share
As for profitability, Transcat has a trailing twelve months EPS of $1.12.
PE Ratio
Transcat has a trailing twelve months price to earnings ratio of 87.43. Meaning, the purchaser of the share is investing $87.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.52%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 242.87M for the twelve trailing months.
7. Regeneron Pharmaceuticals (REGN)
8.3% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.04.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.92. Meaning, the purchaser of the share is investing $26.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Regeneron Pharmaceuticals’s EBITDA is 67.35.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 14% and positive 3.1% for the next.
8. Ducommun Incorporated (DCO)
7.3% sales growth and 3.3% return on equity
Ducommun Incorporated provides engineering and manufacturing products and services primarily to the aerospace and defense, industrial, medical, and other industries in the United States. It operates through two segments, Electronic Systems and Structural Systems. The Electronic Systems segment provides cable assemblies and interconnect systems; printed circuit board assemblies; higher-level electronic, electromechanical, and mechanical components and assemblies, as well as lightning diversion systems; and radar enclosures, aircraft avionics racks, shipboard communications and control enclosures, shipboard communications and control enclosures, wire harnesses, surge suppressors, conformal shields, and other assemblies. It also supplies engineered products, including illuminated pushbutton switches and panels for aviation and test systems; microwave and millimeter switches and filters for radio frequency systems and test instrumentation; and motors and resolvers for motion control. In addition, this segment provides engineering expertise for aerospace system design, development, integration, and testing. The Structural Systems segment designs, engineers, and manufactures contoured aluminum, titanium, and Inconel aero structure components; structural assembly products, such as winglets, engine components, and fuselage structural panels; and metal and composite bonded structures and assemblies comprising aircraft wing spoilers, large fuselage skins, rotor blades on rotary-wing aircraft and components, flight control surfaces, engine components, and ammunition handling systems. It serves commercial aircraft, military fixed-wing aircraft, military and commercial rotary-wing aircraft, and space programs, as well as industrial, medical, and other end-use markets. The company was founded in 1849 and is headquartered in Santa Ana, California.
Earnings Per Share
As for profitability, Ducommun Incorporated has a trailing twelve months EPS of $1.44.
PE Ratio
Ducommun Incorporated has a trailing twelve months price to earnings ratio of 35.09. Meaning, the purchaser of the share is investing $35.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 753.03M for the twelve trailing months.
